Qualified for CNS drug delivery

Disease Area

NEUWAY Pharma`s CNS Drug Delivery Platform allows for the development of causal gene therapies for the treatment of a broad variety of genetic CNS diseases. There are 6,000 known gene defects today - and most of those primarily affect the CNS and are often fatal.

Besides that NEUWAY is working on a new treatment for a rare but frequently fatal neurological disease called progressive multifocal leucoencephalopathy (PML).